Revista Espanola de Cardiologia Suplementos最新文献_第10页

Técnicas de imagen en la fibrilación auricular 心房颤动的成像技术

Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI: 10.1016/S1131-3587(16)30010-3

José Antonio Vázquez de Prada , Leopoldo Pérez de Isla

引用次数: 1

Edoxabán. Propiedades farmacocinéticas y farmacodinámicas 爱德华。药代动力学和药效学特性

Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI: 10.1016/S1131-3587(16)30017-6

Juan Tamargo

{"title":"Edoxabán. Propiedades farmacocinéticas y farmacodinámicas","authors":"Juan Tamargo","doi":"10.1016/S1131-3587(16)30017-6","DOIUrl":"10.1016/S1131-3587(16)30017-6","url":null,"abstract":"<div><p>Edoxaban is a potent, selective, direct, reversible inhibitor of coagulation factor Xa. Because of its mechanism of action, edoxaban prolongs the prothrombin time and the activated partial thromboplastin time and reduces anti-factor-Xa activity. In both in vitro and in vivo models, edoxaban is a more effective antithrombotic than fondaparinux. Given orally, the drug rapidly (i.e. in 1–2 hours) reaches its peak plasma concentration and achieves its maximum effect on various antithrombotic biomarkers (e.g. prothrombin time, activated partial thromboplastin time and anti-factor-Xa activity). Edoxaban (15–150 mg once daily) has a linear pharmacokinetic profile. It is readily absorbed when given orally (the bioavailability is 62%), but, unlike other factor-Xa inhibitors, it exhibits only poor binding to plasma proteins and is not biotransformed via CYP3A4. It is eliminated by biliary and renal routes and has a half-life of 10–14 hours, which enables edoxaban to be administered once daily. Exposure to the drug is independent of age, sex and ethnicity, but increases as the patient's weight and renal function decrease.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30017-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56633980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Estudios en fase III del edoxabán 依多沙班的第三阶段研究

Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI: 10.1016/S1131-3587(16)30019-X

Iñaki Lekuona Goya

引用次数: 0

¿Se está controlando las complicaciones del TAVI? TAVI并发症是否得到控制?

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30022-4

Enrique Gutiérrez, Rocío Angulo, Jaime Elízaga, Francisco Fernández-Avilés

引用次数: 2

La guía europea de dislipemia. Fortalezas y debilidades 欧洲血脂异常指南。优点和缺点

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)70119-6

Eduardo Alegría-Ezquerra , Eduardo Alegría-Barrero , Ana Alegría-Barrero

引用次数: 0

Tratamiento de la insuficiencia cardiaca avanzada en el siglo XXI. El trasplante cardiaco en la encrucijada 21世纪晚期心力衰竭的治疗。心脏移植处于十字路口

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30002-9

Juan F. Delgado Jiménez

引用次数: 0

TAVI: una revolución en cardiología

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30017-0

César Morís, Pablo Avanzas

引用次数: 4

Aspectos organizativos contemporáneos del trasplante cardiaco: visión del clínico 心脏移植的当代组织方面:临床医生的观点

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30004-2

Luis Alonso-Pulpón, Javier Segovia

{"title":"Aspectos organizativos contemporáneos del trasplante cardiaco: visión del clínico","authors":"Luis Alonso-Pulpón, Javier Segovia","doi":"10.1016/S1131-3587(15)30004-2","DOIUrl":"10.1016/S1131-3587(15)30004-2","url":null,"abstract":"<div><p>Heart transplantation in Spain achieved maturity some time ago in terms of outcomes and the number of procedures performed. The main limitation has been a lack of suitable donors. This article reviews strategies currently under discussion for achieving progress in the field, whether by increasing the number of donors, by more rational selection of transplant candidates or by better planning at the national level. The emergence of mechanical circulatory assist devices, used either as a complement or an alternative to transplantation, is the single factor that will have the greatest influence on heart transplantation in the future. Heart failure is a common, chronic and complex condition, whose treatment requires the cooperation of different tiers within the health-care system at the national level. Formal regional networks that enable such cooperation must be established, beginning with the adoption of common terminology. Of particular relevance is the network established for the integrated treatment of cardiogenic shock. Finally, the ongoing training of specialists in the field should be recognized officially. The Spanish Society of Cardiology should take the first steps on the regulatory path towards establishing certification in this subspecialty – this will help harmonize practice in the field of heart failure in Spain with that in other developed countries.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(15)30004-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56632391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Hipotermia terapéutica: ¿lo dejamos? 治疗性体温过低:我们应该停止吗?

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30029-7

Ana Viana Tejedor

{"title":"Hipotermia terapéutica: ¿lo dejamos?","authors":"Ana Viana Tejedor","doi":"10.1016/S1131-3587(15)30029-7","DOIUrl":"10.1016/S1131-3587(15)30029-7","url":null,"abstract":"<div><p>Current international guidelines recommend therapeutic hypothermia for patients who have survived a witnessed cardiac arrest to minimize neurological damage due to postischemic reperfusion. This recommendation is based mainly on the results of two randomized, controlled trials that included 352 patients and on supporting evidence from the field of neonatal asphyxia that also demonstrated the neuroprotective effect of hypothermia. However, the use of hypothermia in the context of a cardiac arrest has been called into question in the wake of a recently published randomized trial that included 939 patients and which found that hypothermia at 33 °C offered no benefits over maintaining a temperature of 36 °C. Moreover, another recent study has questioned the usefulness of starting hypothermia early in the prehospital phase. This article contains a review of the evidence available on the use of hypothermia, areas of uncertainty and strategies for using the technique. It concludes that there is sufficient evidence to support the continued use of hypothermia in the majority of patients who suffer a cardiac arrest and have a heart rhythm susceptible to defibrillation, pending the results of new studies using a range of target temperatures (32-36 °C) and treatment durations.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(15)30029-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56632451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Panorama actual del tratamiento farmacológico del paciente con enfermedad coronaria: de la teoría a la práctica 冠状动脉疾病患者药物治疗的现状概述:从理论到实践

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(16)30003-6

Jesús Álvarez-García, Alessandro Sionis

引用次数: 0